Concurrent inactivation of RB1 and TP53 pathways in anaplastic Oligodendrogliomas

Journal of Neuropathology and Experimental Neurology

Volumn 60, Issue 12, 2001, Pages 1181-1189

  Watanabe, Takao ^a   Yokoo, Hideaki ^a   Yokoo, Minako ^a   Yonekawa, Yasuhiro ^b   Kleihues, Paul ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anaplastic oligodendroglioma; Homozygous deletion; Oligodendroglioma; Promoter methylation; RB1; TP53

Indexed keywords

CYCLIN DEPENDENT KINASE 4; PROTEIN MDM2; PROTEIN P14; PROTEIN P15; PROTEIN P16; RETINOBLASTOMA PROTEIN; TUMOR PROTEIN; TUMOR PROTEIN 53; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER GRADING; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE DISRUPTION; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION;

EID: 0035213384     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/60.12.1181     Document Type: Article

References (53)

1. Oligodendroglioma: Incidence and biological behavior in a defined population
2. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
3. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors
4. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
5. Molecular genetic evidence for subtypes of oligoastrocytomas
6. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
7. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
8. Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors
9. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
10. Genetic aberrations in oligodendroglial tumours: An analysis using comparative genomic hybridization (CGH)
11. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization
12. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas
13. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas
14. Cancer cell cycles
15. ARF, participates in a regulatory feedback loop with p53 and MDM2
16. INK4a, genes in oligodendrogliomas
17. 1-phase progression
18. INK4a and the control of cellular proliferative life span
19. p15INK4B is a potential effector of TGFbeta-induced cell cycle arrest
20. Regulation of the G2/M transition by p53
21. Pathways governing G1/S transition and their response to DNA damage
22. Surfing the p53 network
23. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
24. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
25. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
26. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
27. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
28. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene
29. INK4a genes in human esophageal squamous cell carcinoma
30. Arf deletion and methylation in genetic pathways to glioblastomas
31. ARF)/CDKN2B (p15) gene inactivation in malignant gliomas
32. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
33. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas
34. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
35. Promoter hypermethylation of the RB1 gene in glioblastomas
36. Genetic alterations associated with the evolution and progression of astrocytic brain tumours
37. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
38. p53 mutations in nonastrocytic human brain tumors
39. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2
40. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumours
41. 1-S transition control gene abnormalities
42. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas
43. Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies
44. INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma
45. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia
46. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B
47. p53 and E2F-1 cooperate to mediate apoptosis
48. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens
49. Deletion of p16 and p15 genes in brain tumors
50. INK4b